


Synthetic antibody demonstrates Omicron detection along with all other variants of concern

MIP Diagnostics' synthetic SARS-CoV-2 antibody shown to detect the Omicron variant as well as previously proven Alpha, Beta, Delta and Gamma variants

BEDFORD, BEDFORDSHIRE, UNITED KINGDOM, January 13, 2022 /EINPresswire.com/ -- [MIP Diagnostics](https://www.mipdiagnostics.com/) Ltd. has today announced that its synthetic SARS-CoV-2 antibody ([COVID-19 nanoMIP](#)) can detect the Omicron variant as well as previously proven Alpha, Beta, Delta and Gamma variants of the COVID-19 virus.



SPR Response demonstrating Omicron variant detection

MIP Diagnostics, the leading manufacturer of molecularly imprinted polymers (MIPs) - commonly termed synthetic antibodies - has demonstrated that its COVID-19 nanoMIP can detect the increasingly dominant Omicron variant. The synthetic antibody has already been shown to detect the other variants of concern - Alpha, Beta, Delta and Gamma.

Initial assessment using pharmaceutical grade molecular modelling software demonstrated the COVID-19 nanoMIP should be able to detect the Omicron variant, and this has now been confirmed via laboratory testing. The COVID-19 nanoMIP was shown to detect the SARS-CoV-2 Omicron variant spike protein (Native Antigen Company) in buffer using surface plasmon resonance (SPR), with a magnitude of specific response comparable to other variants of the virus previously tested. Third party validation in a separate sensor device will be carried out shortly.

Originally developed in under 8 weeks, the MIP Diagnostics COVID-19 nanoMIP offers IVD manufacturers a host of benefits including high selectivity and sensitivity, demonstrated to the picogram level in a number of COVID-19 sensor devices. The robust nature of MIPs, when compared to antibodies, will also provide the superior shelf life and storage properties required by the IVD market as self-testing becomes more prevalent across multiple disease states following the COVID-19 pandemic.

Speaking on the new data, Alan Thomson, CTO at MIP Diagnostics said, "In pandemic situations, a fast response is essential, and our advanced molecular modeling software had already been utilised to assess the performance of the COVID-19 nanoMIP against the Omicron variant in-silico. This new data has confirmed our initial findings, and not only demonstrates the capabilities of the COVID-19 nanoMIP, but also supports the wider progress toward robust, non-animal derived reagents in the IVD industry."

Keli Stockbridge
MIP Diagnostics
+44 1234 589725
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/560538029>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.